(PerkinElmer, 2470 WIZARD 2 ) was used to measure radioactivity.
(E)-6-Iodo-2-(4-(methylamino)styryl)-chromone 20 and [ 125 I]20 were prepared by the method in the literature 1 . All final compounds were determined to be ≥95% pure by HPLC analysis (Shimadzu HPLC system, a LC-10AT pump with a SPD-10A UV detector, λ= 254 nm). All animals were supplied by Kyudo, Co., Ltd (Japan). The experiments with animals were conducted in accordance with our institutional guidelines and were approved by Nagasaki University Animal Care Committee.
Chamistry (E)-2-Acetyl-bromophenyl cinnamate (1)
To a mixture of cinnamic acid (740 mg, 5.0 mmol) and thionyl chloride (1.0 mL, 12.9 mmol) was added one drop of DMF and stirred at 80 °C for 1 h. The mixture was evaporated then the residue was added a solution of 5'-bromo-2'-hydroxyacetophenone (1.08 g, 5.0 mmol) in pyridine (10 mL) and stirred under reflux for 2.5 h. The reaction mixture was added to 1 M HCl and the precipitated solid was filtrated to give 1 (1.43 g, 88%) as a white powder. .
(E)-2-Acetyl-bromophenyl-3-(4-methoxyphenyl)acrylate (2)
Using the above procedure for 1 starting fromtrans-4-methoxycinnamic acid, the title compound 2 (696 mg, 75%) was obtained as a white powder. 1 .
(E)-1-(5-Bromo-2-hydroxylphenyl)-3-phenylpent-4-ene-1,3-dione (4)
To a solution of acetophenone 1 (1.43 g, 4.38 mmol) in pyridine (15 mL) was added powdery KOH (220 mg, 3.84 mmol). After stirring for 1 h at 50 ºC, the mixture was treated with ice-cooled 10% aqueous CH3CO2H (20 mL). .
(E)-6-Bromo-2-styrylchromone (7)
To a solution of 4 (1.43 g, 4.14 mmol) in CH3CO2H (10 mL) was added concentrated .
(E)-6-Bromo-2-(4-methoxystyryl)-chromone (8)
Using the above procedure for 7 starting from 5, the title compound 8 (268 mg, 71%) was obtained as a yellow ocher powder. .
(E)-6-Bromo-2-(3,4-dimethoxystyryl)-chromone (9)
Using the above procedure for 7 starting from 6, the title compound 9 (762 mg, 99%) was obtained as a yellow ocher powder. Using the above procedure for 13 starting from 11, the title compound 14 (118 mg, 66%) was obtained as a yellow ocher oil. 1 
(E)-6-Iodo-2-(3,4-dimethoxystyryl)chromone (15)
Using the above procedure for 13 starting from 12 (141 mg, 0.24 mmol), the title compound 15 (104 mg, 99%) was obtained as a yellow ocher oil. 1 H NMR (300 MHz, CDCl3) 
(E)-6-Iodo-2-(4-hydroxylstyryl)-chromone (16)
To a solution of 14 (113 mg, 0.28 mmol) in CH2Cl2 (8.0 mL) was added BBr3 in CH2Cl2 (2.0 mL, 1.0 M). After stirred for 48 h at room temperature, the reaction mixture was quenched with water and then extracted with CHCl3 three times. The combined organic layers were dried with Na2SO4 and evaporated to dryness. The crude product was chromatographed 
(E)-6-Iodo-2-(4-hydroxyethoxystyryl)-chromone (17)
To a solution of 16 (22 mg, 0.056 mmol) in DMF (5.0 mL) was added K2CO3 (387 mg, 
6-Iodo-2-(4'-(4'-hydroxyethoxy)ethoxy)styryl)chromone (18)
Prepared using the above procedure for 17 from 16 and ethylene glycol mono-2-chloroethyl ether , the title compound 18 (9.0 mg, 50%) was obtained as a yellow NaHSO3aq (100 μL). After alkalization with 100 μL of satd. NaHCO3 and extraction with ethyl acetate, the extract was dried by passing it through an anhydrous Na2SO4 column and evaporated to dryness. The crude products were purified by HPLC on a Cosmosil C18 column (Nacalai Tesque, 5C18-AR-II, 4.6×250 mm) with an isocratic solvent of CH3CN/H2O (6:4) at a flow rate of 1.0 mL/min. Because a small amount of Z-isomer was found during the radiosynthesis of 125 I labeled E-isomers of SCs, the separated E-isomer of SCs were kept protected from light until the in vitro and in vivo experiments were performed.
Binding assays using the aggregated Aβ peptide in solution
Binding assays by using filtration techniques were carried out as described previously 2 .
Briefly, a mixture containing 50 μL of test compounds (8 pM-12.5 μM in 10% ethanol), 50 Fluorescence staining on Tg2576 mice brain sections
The Tg2576 mice (female, 22-24 months old) and wild-type mice (female, 24 months old) were used as the Alzheimer's model and control mice, respectively. After the mice were euthanized, the brains were immediately removed and frozen in powdered dry ice. The frozen blocks were sliced into serial sections, 10 μm thick. Each slide was incubated with a 50%
DMSO solution (100 μM) of 14 and 15 for 10 min. The slices were rinsed twice with 50 % DMSO for 1 min, and subsequently dipped into water for 30 s. The fluorescence images were collected by BZ8100 (Keyence) using a DAPI-BP filter set for 14 and 15 (excitation, 360 nm; dichroicmirror, 400 nm; longpass filter, 460 nm) or a GFP-BP filter set for thioflavin-S (excitation, 470 nm; dichroic mirror, 495 nm; longpass filter, 535 nm). Thereafter, the serial sections were also stained with thioflavin-S, a pathological dye commonly used for staining Aβplaques in the brain, and examined using the microscope in the same condition with that of styrylchromone. Then, the adjacent sections were stained with thioflavin S.The fluorescence images were collected by an ECLIPSE 80i microscope (Nicon Corp., Japan) using a B-2A filter set (excitation, 450-490 nm; dichroic mirror, 505 nm; long pass filter, 520 nm).
In vitro autoradiography on

In vivo biodistribution in normal mice
Each 125 I labeled tracer (7.4-14.8 kBq) was injected intravenously via the tail vein into ddY mice (male, 5 weeks old, 25-30 g). The mice were euthanized at 2, 30, 60, 120 and 180 min after injection. The tissues were dissected, weighed and the radioactivity was measured by automated gamma counting. Data were calculated as the percentage of the injected dose per gram (% ID/g).
